Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

Inclusion Criteria: * Signed informed consent * Histologically confirmed Hodgkin's lymphoma * Measurable disease (at least one lesion that can be accurately measured in at least two dimensions with spiral CT scan, min \> 15 mm in the longest diameter or \> 10 mm in the short axis) * World Health Organization (WHO) performance status \< 2 * Relapsed or refractory to at least one prior treatment line * No prior therapy with DHAP or Nivolumab * No severe concurrent illness Exclusion Criteria: * History of HIV * Active Hepatitis B or Hepatitis C infection * Uncontrolled infection (requiring intravenous treatment) at the time of enrollment * Pregnancy or breastfeeding * Somatic or psychiatric disorder making the patient unable to sign informed consent * Active or prior documented autoimmune disease requiring systemic treatment * No receiving a live vaccine within 30 days prior to first dose of nivolumab * History of non-infectious pneumonitis that required steroids * Other malignancy